Details

Autor(en) / Beteiligte

• Jain, Ashokkumar
• Miller, Danielle
• Schreibman, Ian
• Riley, Thomas R.
• Krok, Karen L.
• Dohi, Takehiko
• Sharma, Rajeev
• Kadry, Zakiyah

Titel

Is there increased risk of hepatocellular carcinoma recurrence in liver transplant patients with direct-acting antiviral therapy?

Ist Teil von

• Hepatology international, 2019-03, Vol.13 (2), p.190-198

Ort / Verlag

New Delhi: Springer India

Erscheinungsjahr

2019

Quelle

SpringerLink

Beschreibungen/Notizen

• Background Recently, a controversy has emerged: is the rate of recurrence of hepatocellular carcinoma (HCC) higher following treatment of hepatitis C virus (HCV) with direct-acting antiviral (DAA) therapy? However, the risk of HCC recurrence has not been studied in liver transplant (LTx) recipients who received DAA therapy. The aim of the present study is to compare the rate of HCC recurrence in LTx recipients who did or did not receive DAA therapy. Patients and methods Sixty-three patients received LTx with HCC. Twenty-seven (42.9%) with HCV received DAA therapy (Group A), 20 (31.7%) with HCV did not receive DAA therapy (Group B), and 16 (25.4%) did not have HCV (Group C). Results In group A, three (11%), in group B, one (5%), and in group C, none had recurrence of HCC. Actuarial 4-year recurrence-free survival was 88.9, 95, and 100% in group A, B, and C, respectively ( p  = 0.37). Group A was subdivided into two groups for comparison with Group B: A1 included five patients who had end of treatment response (ETR) without sustained virological response (SVR), and A2 included 20 patients who achieved SVR. Three patients from A1 had HCC recurrence and no patients from A2 had HCC recurrence. ( p  = 0.0038; group A1, A2, and B). Conclusions The rate of HCC recurrence in LTx patients with DAA therapy was significantly higher with ETR, without SVR, after DAA therapy compared to patients with SVR or patients who did not receive DAA therapy. LTx recipients with HCC receiving DAA therapy requires further studies.